NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Commercial Strategy Through Humanitas Collaboration
Regentis Biomaterials (NYSE American: RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy, to support expanding clinical activities and commercial strategy for GelrinC(R) in Europe, where the product has CE Mark approval for knee cartilage repair. The collaboration includes Prof. Elizaveta Kon, an internationally recognized expert in cartilage regeneration and orthopedic innovation, who is expected to help lead development of Regentis’ European Centers of Excellence network, supporting surgeon education, clinical expertise and broader adoption of GelrinC(R) as the company advances commercialization. To view the full press release, visit https://nnw.fm/j7jt0 About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative…







